Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 1;14(15):5417.
doi: 10.3390/jcm14155417.

Comparison Between Transient Elastography and Point Shear Wave Elastography in the Assessment of Liver Fibrosis According to the Grade of Liver Steatosis

Giuseppe Losurdo  1 , Antonino Castellaneta  1 , Claudia Di Nuccio  1 , Paola Dell'Aquila  1 , Ilaria Ditonno  1 , Domenico Novielli  1 , Antonio Continisio  1 , Margherita De Bellis  1 , Alfredo Di Leo  1 , Mariabeatrice Principi  1 , Michele Barone  1
Affiliations

Comparison Between Transient Elastography and Point Shear Wave Elastography in the Assessment of Liver Fibrosis According to the Grade of Liver Steatosis

Giuseppe Losurdo et al. J Clin Med. .

Abstract

Background: Transient elastography (TE), using Fibroscan® and point shear wave elastography (pSWE), are two techniques used to estimate liver fibrosis. The aim of our study was to compare, for the first time, these two techniques in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), stratifying the analysis on the basis of the grades of steatosis. Methods: We recruited 85 consecutive MAFLD patients who underwent liver stiffness (LS) measurement performed by Fibroscan® and pSWE on the same day. Severity of steatosis was estimated by Fibroscan® and expressed as controlled attenuation parameter (CAP), ranging from S0 to S3. Spearman's "r" coefficient was used to calculate the correlation and Bland-Altman graphs was used to evaluate the agreement. Results: In general, the correlation and agreement between Fibroscan® and pSWE were substantial (r = 0.66, p < 0.001 and bias= -0.64 ± 2.48, respectively). When data were analyzed according to the grade of steatosis, an increasing significant correlation was observed going from S0 to S2 (r = 0.79, r = 0.81, and r = 0.85, respectively), whereas a low correlation and agreement were observed for S3 patients (r = 0.48, p = 0.003, bias= -0.95 ± 2.51). Conclusions: Fibroscan® and pSWE are equivalent techniques to estimate liver fibrosis in patients with mild to moderate steatosis, while in presence of severe steatosis their agreement is low.

Keywords: Fibroscan®; fibrosis; liver steatosis; shear wave elastography; stiffness.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
(a) Scatterplot reporting the correlation between Fibroscan® and pSWE in the entire patient’s cohort; (b) Bland–Altman plot in the entire patients’ cohort.
Figure 2
Figure 2
(a) Correlation scatterplot and (b) Bland–Altman plot of S0 patients enrolled in the study.
Figure 3
Figure 3
(a) Correlation scatterplot and (b) Bland–Altman plot of S1 patients enrolled in the study.
Figure 4
Figure 4
(a) Correlation scatterplot and (b) Bland–Altman plot of S2 patients enrolled in the study.
Figure 5
Figure 5
(a) Correlation scatterplot and (b) Bland–Altman plot of S3 patients enrolled in the study.
See this image and copyright information in PMC

References

    1. Marchesini G., Day C.P., Dufour J.F., Canbay A., Nobili V., Ratziu V., Tilg H., Roden M., Gastaldelli A., Yki-Jaevinen H., et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016;64:1388–1402. doi: 10.1016/j.jhep.2016.11.002. - DOI - PubMed
    1. Huang T.D., Behary J., Zekqry A. Non-alcoholic fatty liver disease: A review of epidemiology, risk factors, diagnosis and management. Intern. Med. J. 2020;50:1038–1047. doi: 10.1111/imj.14709. - DOI - PubMed
    1. Leung C., Yeoh S.W., Patrick D., Ket S., Marion K., Gow P., Angus P.W. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J. Gastroenterol. 2015;21:1189–1196. doi: 10.3748/wjg.v21.i4.1189. - DOI - PMC - PubMed
    1. Savari F., Mard S.A. Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment. Heliyon. 2024;10:e28468. doi: 10.1016/j.heliyon.2024.e28468. - DOI - PMC - PubMed
    1. Bedossa P. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential. Liver Int. 2018;38((Suppl. S1)):64–66. doi: 10.1111/liv.13653. - DOI - PubMed

LinkOut - more resources